# Kisspeptin Dosage in the Research Literature

> Kisspeptin dosage data from published clinical trials: IV bolus, continuous infusion, subcutaneous injection, and intranasal administration protocols — routes, magnitudes, and outcomes cited.

## Overview

Kisspeptin dosage data summarized here are drawn exclusively from published clinical research. All doses cited were administered to human participants in supervised research settings. Kisspeptin is not approved for any clinical indication; no doses here constitute therapeutic or personal recommendations.

## Intravenous bolus — kisspeptin-10 in men

George et al. (2011, JCEM) administered kisspeptin-10 as IV bolus doses of 0.3, 1.0, and 3.0 µg/kg to healthy men. [5] Dose-dependent LH elevation within minutes. At 1.5 µg/kg/h continuous IV infusion, mean LH rose from 5.2 to 14.1 IU/L; LH pulse frequency increased from 0.7 to 1.0 pulses/hour; testosterone was elevated.

In men with type 2 diabetes and mild hypogonadism, a 0.3 µg/kg IV bolus raised LH approximately 2-fold and normalized testosterone over 11 hours (George 2013, Clinical Endocrinology). [6]

### How long does it take for kisspeptin to kick in?

LH rises were observed within minutes of IV bolus administration. KP-10's approximately 4-minute plasma half-life explains the rapid onset. [5][6]

## Intravenous infusion — kisspeptin-54 in hypothalamic amenorrhea

Jayasena et al. (2014, JCEM) used continuous IV infusion of kisspeptin-54 at doses from 0.01 to 1.00 nmol/kg/h. LH pulse frequency increased approximately 3-fold at effective doses. Higher doses (1.0 nmol/kg/h) showed desensitization over prolonged infusion. [7]

Jayasena et al. (2009, JCEM) studied subcutaneous kisspeptin-54 twice daily for 14 days. Acute LH response on day 1: ~24 IU/L. After 14 days, LH response fell to ~2.5 IU/L — marked tachyphylaxis. [8]

## Subcutaneous injection — IVF oocyte maturation trigger

The Abbara 2015 Phase 2 RCT (n=60) evaluated single SC doses of kisspeptin-54 at 3.2, 6.4, 9.6, and 12.8 nmol/kg. [9]

- 9.6 nmol/kg: 95% oocyte maturation, 62% live birth rate
- Zero moderate, severe, or critical OHSS at any dose

## Kisspeptin half-life

**KP-10.** Plasma half-life approximately 4 minutes in humans: 3.8 ± 0.3 min in men, 4.1 ± 0.4 min in women. Complete clearance approximately 30 minutes after IV bolus. [12]

**KP-54.** Plasma half-life approximately 27–32 minutes in humans. The roughly 8-fold difference results from KP-54's larger molecular size (6142 Da versus 1302.5 Da). [12]

## Kisspeptin side effects observed in trials

A 2025 systematic review documented no serious adverse events across more than 1,000 kisspeptin administrations (Velmurugan 2025, Current Medicinal Chemistry). [22]

The principal pharmacological concern is tachyphylaxis with chronic administration. Continuous high-dose IV infusion and twice-daily SC protocols both showed KISS1R desensitization. [7][8] This is a pharmacological limitation, not an acute safety concern.

## References

[5] George JT, et al. Kisspeptin-10 is a potent stimulator of LH in men. JCEM. 2011. https://pubmed.ncbi.nlm.nih.gov/21632807/
[6] George JT, et al. Kisspeptin-10 stimulates LH and testosterone in men with type 2 diabetes. Clinical Endocrinology. 2013. https://onlinelibrary.wiley.com/doi/10.1111/cen.12103
[7] Jayasena CN, et al. Increasing LH Pulsatility in Women With Hypothalamic Amenorrhoea. JCEM. 2014. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4207927/
[8] Jayasena CN, et al. Subcutaneous kisspeptin-54 causes tachyphylaxis with chronic administration. JCEM. 2009. https://pubmed.ncbi.nlm.nih.gov/19820030/
[9] Abbara A, et al. Efficacy of Kisspeptin-54 to Trigger Oocyte Maturation in Women at High Risk of OHSS. JCEM. 2015. https://pubmed.ncbi.nlm.nih.gov/26192876/
[10] Jayasena CN, et al. Kisspeptin-54 triggers egg maturation in women undergoing IVF. JCI. 2014. https://pubmed.ncbi.nlm.nih.gov/25036713/
[11] Abbara A, et al. A second dose of kisspeptin-54 improves oocyte maturation. Human Reproduction. 2017. https://pubmed.ncbi.nlm.nih.gov/28854728/
[12] d'Anglemont de Tassigny X, et al. Mechanistic insights into KP-54 vs KP-10 in vivo. PLoS One. 2017. https://pmc.ncbi.nlm.nih.gov/articles/PMC5413024/
[21] Kisspeptin Does Not Affect Anxiety in Humans. JCEM. 2025. https://pubmed.ncbi.nlm.nih.gov/40036336/
[22] Velmurugan H, et al. Kisspeptin and its Current Clinical Status. Current Medicinal Chemistry. 2025. https://pubmed.ncbi.nlm.nih.gov/38265397/
[24] Intranasal kisspeptin administration rapidly stimulates gonadotropin release. eBioMedicine. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12018048/

---

The KISS1 record — mechanism, isoforms, and clinical trials — indexed here. Not a clinic, not a vendor.